Medable to enhance digital real-world evidence research network

14th August 2019 (Last Updated August 14th, 2019 00:00)

US-based data-driven clinical trials provider Medable is set to join the American Heart Association’s Center for Health Technology & Innovation Innovators Network to improve a patient-centric digital system that connects patients and researchers.

US-based data-driven clinical trials provider Medable is set to join the American Heart Association’s Center for Health Technology & Innovation Innovators Network to improve a patient-centric digital system that connects patients and researchers.

The centre focuses on building health-technology relationships and is involved in providing new and scalable solutions across the health industry.

It enables members of its ‘Innovators Network’ to integrate their technology with the association’s digital resources to encourage the adoption of digital healthcare solutions and services.

Medable primarily joins the network to advance the understanding and treatment of cardiovascular disease.

The platform will aim to improve patient care by providing a customised digital experience, as well as advance research by capturing patient-reported data of EMR and clinical outcomes assessment.

The collected data will be available to patients and research partners in the ‘Human Heart Digitome’ powered by Medable’s analytics system.

With a strong commitment to developing the largest digital real-world evidence data, the collaboration aims to advance the understanding and treatment of cardiovascular disease.

Medable’s collaboration with the American Heart Association is expected to significantly improve clinical care and clinical research.

The registered participants will receive clinical guidance, along with personalised digital CarePlans and advancing research through secured data generation on the Medable platform.

Medable co-founder and CEO Michelle Longmire said: “The Human Heart Digitome, a digital real-world evidence patient registry created on Medable’s end-to-end platform, will enable physicians and researchers to better identify at-risk patients using Medable’s predictive analytics platform, improve health outcomes and bring new cardiovascular therapies to patients faster.”